Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
| Status: | Completed |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/23/2018 |
| Start Date: | April 12, 2017 |
| End Date: | May 30, 2018 |
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
An observational time and motion study in a clinical oncology setting is utilized in order to
measure and compare product attributes and overall product efficiency between lanreotide and
octreotide LAR.
measure and compare product attributes and overall product efficiency between lanreotide and
octreotide LAR.
Inclusion Criteria:
- Men and women must be 18 years of age or older
- A current diagnosis of advanced, unresectable GEP-NET
- Provided written informed consent to participate in the study
- Currently receiving lanreotide or octreotide LAR and has received at least one prior
injection of current somatostatin analogues (SSA).
Exclusion Criteria:
- Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
- Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate
more than 1 injection on the same day
- Scheduled to receive any other treatment in the infusion center/room on the same day
and as part of the same appointment
- Known hypersensitivity to somatostatin analogues
We found this trial at
5
sites
Click here to add this to my saved trials
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials